We are thrilled to attend the BioCT Connecticut Rare Disease Forum on March 17th in Farmington, CT. The event will feature industry-led discussions on the latest developments in rare disease diagnostics and treatment. Swing by our table to grab some swag and discover how Biocytogen is accelerating the drug discovery process.
What is BioCT?
BioCT connects Connecticut’s pharmaceutical, life sciences, medical device, healthcare and digital health communities in support of the state’s innovation ecosystem. Through strategic partnerships with leading academic and research institutions, as well as targeted programs and events, they create many opportunities to network and exchange knowledge. Their mission is to accelerate growth in the life science sector and position Connecticut as a hub for discovery.
Event Overview
Date: March 17th, 2026
Venue: The Jackson Laboratory For Genomic Medicine, 10 Discovery Dr, Farmington, CT 06032
Event Schedule
For more information about BioCt, please refer to their website here.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s shape the future of drug discovery together, we look forward to meeting you in Connecticut!
